Update on First Biomarker-Directed Trial of Non-Muscle-Invasive Bladder Cancer
Better Edge : A Northwestern Medicine podcast for physicians
English - July 20, 2022 05:00 - 21.2 MB - ★★★★★ - 2 ratingsHealth & Fitness northwestern medicine better edge research Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Erdafitinib (balversa), an oral pan-fibroblast growth factor receptor (FGFR) 1-4 inhibitor, is being used in one of the first biomarker-directed trials of high-risk non-muscle-invasive bladder cancer (NMIBC). The Thor-2 trial (NCT04172675) targets tumors with driver mutations in the FGFR3 gene. This gene is altered in 40% to 70% of early-stage bladder cancers and may be a rare driver mutation in bladder cancer. If successful, Erdafitinib would the first precision therapy for early stage bladder cancer.
In this podcast episode, lead investigator Joshua J. Meeks, MD, PhD, the Edward M. Schaeffer, MD, PhD Professor of Urology and associate professor of Urology and of Biochemistry and Molecular Genetics at Northwestern Medicine, explains the Thor-2 trial and how it could be a new paradigm in bladder oncology.
Disclosure Statement:
Joshua J. Meeks, MD, PhD has received consulting-related fees from Janssen.
